Clinical Trial Update: A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 pilot trial assessing ruxolitinib in secondary hemophagocytic syndrome has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Syndrome

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Hemophagocytic Syndrome (HPS) | Phase 2 | Status: COMPLETED | Results posted: 2020-11-18